Literatura académica sobre el tema "Differentiation checkpoint"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Differentiation checkpoint".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Differentiation checkpoint"
Polesskaya, Anna y Michael A. Rudnicki. "A MyoD-Dependent Differentiation Checkpoint". Developmental Cell 3, n.º 6 (diciembre de 2002): 757–58. http://dx.doi.org/10.1016/s1534-5807(02)00372-6.
Texto completoMunz, Barbara, Eberhard Hildt, Matthew L. Springer y Helen M. Blau. "RIP2, a Checkpoint in Myogenic Differentiation". Molecular and Cellular Biology 22, n.º 16 (15 de agosto de 2002): 5879–86. http://dx.doi.org/10.1128/mcb.22.16.5879-5886.2002.
Texto completoSell, Stewart y Zoran Ilic. "Comparison of survivor scores for differentiation therapy of cancer to those for checkpoint inhibition: Half full or half empty". Tumor Biology 41, n.º 9 (septiembre de 2019): 101042831987374. http://dx.doi.org/10.1177/1010428319873749.
Texto completoVining, Kyle H., Anna E. Marneth, Kwasi Adu-Berchie, Christina M. Tringides, Joshua M. Grolman, Yutong Liu, Waihay J. Wong et al. "Mechanical Checkpoint Regulates Monocyte Differentiation in Fibrotic Matrix". Blood 138, Supplement 1 (5 de noviembre de 2021): 2539. http://dx.doi.org/10.1182/blood-2021-147297.
Texto completoPuri, Pier Lorenzo, Kunjan Bhakta, Lauren D. Wood, Antonio Costanzo, Jiangyu Zhu y Jean Y. J. Wang. "A myogenic differentiation checkpoint activated by genotoxic stress". Nature Genetics 32, n.º 4 (4 de noviembre de 2002): 585–93. http://dx.doi.org/10.1038/ng1023.
Texto completoKrauss, Jennifer L., Rong Zeng, Cynthia L. Hickman-Brecks, Justin E. Wilson, Jenny P. Y. Ting y Deborah V. Novack. "NLRP12 provides a critical checkpoint for osteoclast differentiation". Proceedings of the National Academy of Sciences 112, n.º 33 (3 de agosto de 2015): 10455–60. http://dx.doi.org/10.1073/pnas.1500196112.
Texto completoRoth, Therese M., C. Y. Ason Chiang, Mayu Inaba, Hebao Yuan, Viktoria Salzmann, Caitlin E. Roth y Yukiko M. Yamashita. "Centrosome misorientation mediates slowing of the cell cycle under limited nutrient conditions in Drosophila male germline stem cells". Molecular Biology of the Cell 23, n.º 8 (15 de abril de 2012): 1524–32. http://dx.doi.org/10.1091/mbc.e11-12-0999.
Texto completoRabadi, Dina, Alia A. Sajani, Randolph J. Noelle y J. Louise Lines. "The role of VISTA in the tumor microenvironment". Journal of Cancer Metastasis and Treatment 8, n.º 5 (2022): 24. http://dx.doi.org/10.20517/2394-4722.2022.06.
Texto completoAbbadi, Dounia, Ming Yang, Devon M. Chenette, John J. Andrews y Robert J. Schneider. "Muscle development and regeneration controlled by AUF1-mediated stage-specific degradation of fate-determining checkpoint mRNAs". Proceedings of the National Academy of Sciences 116, n.º 23 (21 de mayo de 2019): 11285–90. http://dx.doi.org/10.1073/pnas.1901165116.
Texto completoDirlam, Alexandra, Benjamin T. Spike y Kay F. Macleod. "E2f-2 Regulates Caspase-3 Expression and Mitotic Checkpoint Control during End-Stage Erythroid Maturation." Blood 106, n.º 11 (16 de noviembre de 2005): 307. http://dx.doi.org/10.1182/blood.v106.11.307.307.
Texto completoTesis sobre el tema "Differentiation checkpoint"
Shirazi, Fard Shahrzad. "The Heterogenic Final Cell Cycle of Retinal Horizontal Cells". Doctoral thesis, Uppsala universitet, Medicinsk utvecklingsbiologi, 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-222559.
Texto completoWang, Jianwei [Verfasser]. "Batf defines a differentiation checkpoint limiting hematopoietic stem cell self renewal in response to DNA damage / Jianwei Wang". Ulm : Universität Ulm. Fakultät für Naturwissenschaften, 2012. http://d-nb.info/1023728540/34.
Texto completoDavid, Laure. "Etude de nouvelles fonctions de la protéine checkpoint kinase 1 (Chk1) au cours de la différenciation myéloïde normale et leucémique". Thesis, Toulouse 3, 2016. http://www.theses.fr/2016TOU30179/document.
Texto completoThe cell cycle is a series of events that takes place in a mother cell, leading to its division into two daughter cells. The protein Checkpoint kinase 1 (Chk1) is mandatory for its coordinated progression. In this PhD projet, we wondered on the one hand whether Chk1 could be involved in the platelets production process, because these componants of blood that enables coagulation are produced due to a particular cell cycle dedicated to this end. On the other hand, we studied the role of Chk1 in Acute Myeloid Leukemia (LAM) physiopathology. LAM is a cancer of blood cells, in which patients are treated with drugs that create DNA damages, causing the death of tumoral cells. The role of Chk1 in the drug response in LAM is not well studied, but, as it enables DNA repair, it may render theses medicines less efficient, leading to relapses to therapies. So the goal of this project is to check wether Chk1 favors the resistance of some LAM cells to chemotherapeutic treatments
Cartel, Maëlle. "Fonctions et régulations de la kinase CHK1 dans l'hématopoïèse normale et leucémique". Thesis, Toulouse 3, 2019. http://www.theses.fr/2019TOU30150.
Texto completoThe protein Checkpoint kinase 1 (CHK1) acts as a double agent. Indeed, CHK1 is a key player in the cell cycle, both in a normal cellular context and stress conditions such as DNA damage. The goal of my PhD project was to evaluate the functions and regulation of this protein in these two contexts, working on normal and leukemic hematopoiesis. Several studies have already described a role of CHK1 in normal hematopoiesis, but the mechanisms behind the importance of CHK1 in differentiation, particularly in megakaryopoiesis, remain to be elucidated. In addition, CHK1 has proven to be important in Acute Myeloid Leukemia (AML), particularly in the context of resistance to chemotherapy. To better understand the biology of AML, and identify ways to target CHK1, it is necessary to decipher how this kinase is regulated in this context. These two axes have been the backbone of my thesis work, which aims to better define the CHK1 kinase role in these two cellular contexts. It highlights a role for CHK1 in normal megakaryopoiesis, possibly by regulating the activity of the NF-E2 transcription factor. In addition, in the context of Acute Myeloid Leukemia, this work identifies the USP7 deubiquitynase as a major regulator of CHK1 protein levels in AML, and as a new interesting therapeutic target in this pathology
Maduna, Tando Lerato. "Vasoactive intestinal peptide (VIP) controls the development of the nervous system and its functions through VPAC1 receptor signalling : lessons from microcephaly and hyperalgesia in VIP-deficient mice". Thesis, Strasbourg, 2017. http://www.theses.fr/2017STRAJ009/document.
Texto completoThe studies carried out during my PhD demonstrate that VIP-deficient mice suffer from microcephaly and as well as white matter deficits mainly due to the absence of maternal VIP during embryogenesis, Placental secretion of VIP is dependent on T lymphocytes and could be altered in pathologies of the immune system. Moreover, our data links VIP deficiency to sensory alterations, specifically, the nociceptive system. Thus, it is possible that early developmental defects and hypersensitivity to mechanical and cold stimuli are two manifestations of the same pathology. This hypothesis was reinforced following analysis of spontaneous firing patterns of neurons in the sensory thalamus of anesthetized adult males. Neurons from VIP-KO mice are hyperactive, which suggests aberrant local processing of nociceptive input or that the inhibitory inputs from local interneuron networks is reduced
Ullah, Matti. "Immune Checkpoints in Peritoneal Carcinomatosis : HLA-G, PD-L1 & the Impact of Cancer Therapies". Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS288.
Texto completoPeritoneal carcinomatosis (PC) is a term used for widespread metastatic dissemination of cancer to the peritoneal cavity. It is characterized by the accumulation of fluid called “ascites” and is considered a terminal stage of cancer, as it is hard to treat. The overall survival rate for untreated patients is six-months. However, owing to modern techniques like HIPEC, the survival rate can be increased up to five years. The ascites accumulated in PC, consists of tumor cells, cytokines and immune cells. Cancer cells express specific proteins to suppress immune cells activity and their attack, known as immune checkpoints. PD-1/PD-L1 and CTLA-4 are well established immune checkpoint pathways adapted by cancer in evading immunity. Recently, HLA-G has been recognized as an immune checkpoint and has been found to decrease overall survival in several types of solid cancers. We evaluated the expression of HLA-G in ascites from ovarian carcinomatosis. We found that HLA-G is expressed by cancer cells in ascites from all of the patients(n=16) with ovarian carcinomatosis. Moreover, increased levels of sHLA-G1 and HLA-G5 were found in ascites. This presence of sHLA-G isoforms was found to be positively correlated with Tregs and negatively correlated with cytotoxic T-cells (CD8) and NK-cells suggesting the role of HLA-G in immune suppression. Further, we found that ascites can induce the expression of HLA-G in “Hospicells” via inflammatory cytokines. Among the inflammatory cytokines, TGF-β and IL-1β are of crucial importance in HLA-G induction with IL-1β being more potent compared to TGF-β. Further, we found that IL-1β induces HLA-G expression through NF-κB pathway.In a separate cohort of peritoneal carcinomatosis(n=27), consisting of patients with cancer from a different origin, we found that cancer cell cluster in ascites (n=23) had a heterogeneous gene expression of PD-L1, CTLA-4 and HLA-G. Further, we found that all of the patients presented soluble levels of HLA-G in their ascites. However, one patient was negative for soluble PD-L1 and only 5 patients presented soluble CTLA-4 levels in their ascites. This heterogeneity explains why some of the patients respond to immune therapy while others don’t. This also suggests the need for prescreening patients before immune therapy. Moreover, we found a very strong positive correlation (rs=0.793) between gene level of PD-L1 and CTLA-4, while no correlation was found for HLA-G with PD-L1 and CTLA-4 suggesting that HLA-G acts independently of both the immune checkpoints. Also, we evaluated the expression of these immune checkpoints by cells in peritoneal tissue (n=20). We found low expression of HLA-G and PD-L1, but the majority of the samples were found strongly positive for sHLA-G presence. This sHLA-G can provide an immune-suppressive environment for the attachment of the cancer cell clusters to the peritoneal membrane to form cancer nodule. Additionally, we developed an in-vitro cytotoxicity assay to show that the ascites can provide the immune-suppressive action by interfering with immune cell interaction and delaying the lysis of cancer cells by the immune cells.In parallel, we found that the differentiation of the cancer cells results in increased expression of immune checkpoints like HLA-G or PD-L1. This may render these cells more immune resistant and can protect against immune attack. However, in-vivo mice model is needed to study the oncogenic potential of these differentiated cells. Further, we report that the expression of HLA-G and PD-L1 is dependent on the cell cycle phase. The cancer cells, if blocked in mitotic phase express high levels of HLA-G and PD-L1, while lowest expression was observed in G1-phase. Therefore, we suggest avoiding the use of mitotic inhibitors as it may increase the immune suppression of cancer. Moreover, as Ki-67 is directly related to the mitotic index, we suggest developing a Ki-67 scale to evaluate the immune-suppressive profile of cancer patients
Capítulos de libros sobre el tema "Differentiation checkpoint"
de Medina-Redondo, María y Patrick Meraldi. "The Spindle Assembly Checkpoint: Clock or Domino?" En Results and Problems in Cell Differentiation, 75–91. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-19065-0_4.
Texto completoRamaswamy, Madhu, Sophia Y. Clel, Anthony C. Cruz y Richard M. Siegel. "Many Checkpoints on the Road to Cell Death:Regulation of Fas–FasL Interactions and Fas Signaling in Peripheral Immune Responses". En Results and Problems in Cell Differentiation, 17–47. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/400_2008_24.
Texto completoStreicher, Ruth. "Checkpoints". En Uneasy Military Encounters, 37–62. Cornell University Press, 2020. http://dx.doi.org/10.7591/cornell/9781501751325.003.0003.
Texto completoP. Chapoval, Svetlana y Andrei I. Chapoval. "Costimulation in Allergic Asthma: The Roles of B7 and Semaphorin Molecules". En Recent Advances in Asthma Research and Treatments. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.102631.
Texto completoActas de conferencias sobre el tema "Differentiation checkpoint"
Zapp, B., P. Lehmkuhl, H. Schulze-Koops y A. Skapenko. "P022 Checkpoint inhibitors activate store-operated CA2+ entry and ERK1/2 signalling and promote TH17 differentiation". En 38th European Workshop for Rheumatology Research, 22–24 February 2018, Geneva, Switzerland. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-ewrr2018.47.
Texto completoRamalho, Tarciane Campos, Rafael Victor Moita Minervino, IsaIbela Campos Ramalho, Jean Fabricio de Lima Pereira y Og Arnaud Rodrigues. "METAPLASTIC CARCINOMA OF THE BREAST WITH CHONDROID-TYPE MESENCHYMAL DIFFERENTIATION: A CASE REPORT". En XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1055.
Texto completo